Takashi Masuko1, Koichi Takao2, Keijiro Samejima3, Akira Shirahata4, Kazuei Igarashi5, Robert A Casero6, Yasuo Kizawa1, Yoshiaki Sugita7. 1. Laboratory of Physiology and Anatomy, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan. 2. Laboratory of Bioorganic Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1 Keyaki-dai, Sakado, Saitama 350-0295, Japan. Electronic address: ktakao@josai.ac.jp. 3. Translational Medical Research Center, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan. 4. Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1 Keyaki-dai, Sakado, Saitama 350-0295, Japan. 5. Amine Pharma Research Institute, Innovation Plaza at Chiba University, 1-8-15 Inohana, Chuo-ku, Chiba 260-0856, Japan; Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan. 6. The Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore MD21231, USA. 7. Laboratory of Bioorganic Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1 Keyaki-dai, Sakado, Saitama 350-0295, Japan.
Abstract
Inhibitors for polyamine oxidizing enzymes, spermine oxidase (SMOX) and N1-acetylpolyamine oxidase (PAOX), were designed and evaluated for their effectiveness in a photochemically induced thrombosis (PIT) mouse model. N1-Nonyl-1,4-diaminobutane (C9-4) and N1-tridecyl-1,4-diaminobutane (C13-4) competitively inhibited the activity of PAOX and SMOX in a manner comparable to N1,N4-bis(2,3-butadienyl)-1,4-butanediamine (MDL72527), an irreversible inhibitor of both enzymes. The two compounds were then tested for their effects in the PIT model. Both intraperitoneal (i.p.) and intracerebroventricular (i.c.v.) administration of C9-4 decreased infarct volumes significantly. By contrast, C13-4 reduced the volume of brain infarction by i.c.v. administration, but no reduction was observed after i.p. administration. C9-4 administered by i.p. injection reduced the volume of brain infarction significantly at doses of more than 3 mg/kg, and the dosage of 5 mg/kg or 10 mg/kg demonstrated the most potent effect and were more effective than equivalent doses of the other inhibitors such as MDL72527 and N-benzylhydroxylamine. I.P. injection of 5 mg/kg of C9-4 provided a therapeutic time window of longer than 12 h. This report demonstrates that C9-4 is a potent inhibitor of the polyamine oxidizing enzymes and is useful lead compound for candidate drugs with a long therapeutic time window, to be used in the treatment of ischemic stroke.
Inhibitors for polyamine oxidizing enzymes, n class="Gene">spermine oxidase (SMOX) and N1-acetylpolyamine oxidase (PAOX), were designed and evaluated for their effectiveness in a photochemically induced thrombosis (PIT) mouse model. N1-Nonyl-1,4-diaminobutane (C9-4) and N1-tridecyl-1,4-diaminobutane (C13-4) competitively inhibited the activity of PAOX and SMOX in a manner comparable to N1,N4-bis(2,3-butadienyl)-1,4-butanediamine (MDL72527), an irreversible inhibitor of both enzymes. The two compounds were then tested for their effects in the PIT model. Both intraperitoneal (i.p.) and intracerebroventricular (i.c.v.) administration of C9-4 decreased infarct volumes significantly. By contrast, C13-4 reduced the volume of brain infarction by i.c.v. administration, but no reduction was observed after i.p. administration. C9-4 administered by i.p. injection reduced the volume of brain infarction significantly at doses of more than 3 mg/kg, and the dosage of 5 mg/kg or 10 mg/kg demonstrated the most potent effect and were more effective than equivalent doses of the other inhibitors such as MDL72527 and N-benzylhydroxylamine. I.P. injection of 5 mg/kg of C9-4 provided a therapeutic time window of longer than 12 h. This report demonstrates that C9-4 is a potent inhibitor of the polyamine oxidizing enzymes and is useful lead compound for candidate drugs with a long therapeutic time window, to be used in the treatment of ischemic stroke.
Authors: Adam P Mecca; Robert W Regenhardt; Timothy E O'Connor; Jason P Joseph; Mohan K Raizada; Michael J Katovich; Colin Sumners Journal: Exp Physiol Date: 2011-06-17 Impact factor: 2.969
Authors: Jun Li; Martin C Henman; Jeffrey Atkinson; Solomon Fixon-Owoo; Turgut Tatlisumak; Graham G Shaw; Karen M Doyle Journal: Brain Res Date: 2006-02-13 Impact factor: 3.252
Authors: Takeru Shimizu; Robert M Dietz; Ivelisse Cruz-Torres; Frank Strnad; Ana K Garske; Myriam Moreno; Venugopal R Venna; Nidia Quillinan; Paco S Herson Journal: Exp Neurol Date: 2016-06-15 Impact factor: 5.330
Authors: Steven Holshouser; Matthew Dunworth; Tracy Murray-Stewart; Yuri K Peterson; Pieter Burger; Joy Kirkpatrick; Huan-Huan Chen; Robert A Casero; Patrick M Woster Journal: Medchemcomm Date: 2019-02-08 Impact factor: 3.597
Authors: T T Dunston; M A Khomutov; S B Gabelli; T M Stewart; J R Foley; S N Kochetkov; A R Khomutov; R A Casero Journal: Acta Naturae Date: 2020 Jul-Sep Impact factor: 1.845
Authors: Elsie Diaz; Suraj Adhikary; Armand W J W Tepper; Daniel Riley; Rodrigo Ortiz-Meoz; Daniel Krosky; Christophe Buyck; Carolina Martinez Lamenca; Josep Llaveria; Lichao Fang; Jay H Kalin; Vincent N A Klaren; Shorouk Fahmy; Paul L Shaffer; Robert Kirkpatrick; Rodrigo J Carbajo; Maren Thomsen; Antonietta Impagliazzo Journal: Commun Biol Date: 2022-08-05